StocksMediumUpdated•Originally published 6 November 2026•Updated 6 November 2026•
1 min read
Anika Therapeutics Beats Q3 Earnings Estimates and Raises Full-Year 2026 Guidance
Key Facts
1Anika's Q3 revenue increased 10% year-over-year, driven by 17% growth in commercial channels.
2The company raised the lower end of its full-year 2026 revenue guidance and increased its adjusted EBITDA guidance.
3The company secured a new 10-year Hyvisc partnership with enhanced economics.
Anika Therapeutics reported quarterly earnings of $0.29 per share in the third quarter of 2026, beating analyst estimates of $0.17 per share. The company stated in a GlobeNewswire release that revenue increased 10% year-over-year to $30.6 million, up from earnings of $0.04 per share a year ago.
Performance was driven by 17% growth in commercial channels, including a more than 30% increase in Integrity revenue. The company raised the lower end of its full-year 2026 revenue guidance and increased its adjusted EBITDA targets, while ANIK stock closed at $19.33 on November 5, 2026.